Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This is a single-center, open-label, randomized, parallel group study in male and female healthy subjects that aimed to compare the PK and PD profiles of cholecalciferol (DIBASE®, Abiogen Pharma, Italy) administered as repeated once daily (10,000 IU/day for 8 weeks followed by 1000 IU daily for 4 weeks; group A), weekly (50,000 IU/week for 12 weeks; group B) and alternate week doses (100,000 IU every other week for 12 weeks; group C).

Source: 2.1. Patients and Study Design. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This is a single-center, open-label, randomized, parallel group study in male and female healthy subjects that aimed to compare the PK and PD profiles of cholecalciferol (DIBASE®, Abiogen Pharma, Italy) administered as repeated once daily (10,000 IU/day for 8 weeks followed by 1000 IU daily for 4 weeks; group A), weekly (50,000 IU/week for 12 weeks; group B) and alternate week doses (100,000 IU every other week for 12 weeks; group C).

Source: Methods.

After the screening, eligible patients were randomized in a 1:1:1 ratio.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effects on Serum Inflammatory Cytokines of Cholecalciferol Supplementation in Healthy Subjects with Vitamin D Deficiency

Study design awaiting verification · Nutrients · 2022

Original publication title

Effects on Serum Inflammatory Cytokines of Cholecalciferol Supplementation in Healthy Subjects with Vitamin D Deficiency

Angelo Fassio; Davide Gatti; Maurizio Rossini; Davide Bertelle; Riccardo Bixio; Ombretta Viapiana; Stefano Milleri; Camilla Benini; Francesca Pistillo; Giulia Zanetti; Giovanni Adami

© 2022 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The effects of different cholecalciferol supplementation regimens on serum inflammatory cytokines in healthy subjects with vitamin D deficiency are still lacking. This is a single-center, open-label, randomized, parallel group study involving healthy subjects deficient in vitamin D (baseline 25OHD < 20 ng/mL) receiving oral cholecalciferol with three different dosing regimens: Group A: 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks; Group B: 50,000 IU/week for 12 weeks and Group C: 100,000 IU every other week for 12 weeks.

IL-17A, IL-6, IL-8, IL-10, IL-23 and TNFα were measured at baseline and at week 4, 8, 12, and 16. 75 healthy subjects were enrolled (58.7% female), with an average age of 34.1 ± 10.2 years. No statistical differences were observed among groups at baseline for either IL-6, IL-17A, IL-23, IL-8 or IL-10 at any time point; TNFα was indetectable. Concerning the whole sample, the time trend analysis showed a statistically significant linear trend for decreasing values over the treatment period for IL-6 (p = 0.016) and IL-17A (p = 0.006), while no significant time trends were observed for the other teste cytokines.

No significant differences were found in the serum concentrations of the tested cytokines between week 12 and week 16. In young healthy individuals deficient in vitamin D, cholecalciferol administration showed a decrease in the serum IL-6 and IL-17A concentrations, without marked differences using the three regimens.

Authors’ abstract

The effects of different cholecalciferol supplementation regimens on serum inflammatory cytokines in healthy subjects with vitamin D deficiency are still lacking. This is a single-center, open-label, randomized, parallel group study involving healthy subjects deficient in vitamin D (baseline 25OHD < 20 ng/mL) receiving oral cholecalciferol with three different dosing regimens: Group A: 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks; Group B: 50,000 IU/week for 12 weeks and Group C: 100,000 IU every other week for 12 weeks.

IL-17A, IL-6, IL-8, IL-10, IL-23 and TNFα were measured at baseline and at week 4, 8, 12, and 16. 75 healthy subjects were enrolled (58.7% female), with an average age of 34.1 ± 10.2 years. No statistical differences were observed among groups at baseline for either IL-6, IL-17A, IL-23, IL-8 or IL-10 at any time point; TNFα was indetectable. Concerning the whole sample, the time trend analysis showed a statistically significant linear trend for decreasing values over the treatment period for IL-6 (p = 0.016) and IL-17A (p = 0.006), while no significant time trends were observed for the other teste cytokines.

No significant differences were found in the serum concentrations of the tested cytokines between week 12 and week 16. In young healthy individuals deficient in vitamin D, cholecalciferol administration showed a decrease in the serum IL-6 and IL-17A concentrations, without marked differences using the three regimens.

Publication and source details

Original title: Effects on Serum Inflammatory Cytokines of Cholecalciferol Supplementation in Healthy Subjects with Vitamin D Deficiency

Angelo Fassio; Davide Gatti; Maurizio Rossini; Davide Bertelle; Riccardo Bixio; Ombretta Viapiana; Stefano Milleri; Camilla Benini; Francesca Pistillo; Giulia Zanetti; Giovanni Adami

Nutrients · 2022

* Correspondence: davide.bertelle@gmail.com; Tel.: +39-045-812-3155
†

These authors contributed equally to this work.

© 2022 by the authors.2022https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Abiogen Pharma, Pisa, ItalyThe study was financially supported by an unrestricted grant from Abiogen Pharma, Pisa, Italy. The funder had no role in the design, performance, analysis, interpretation or reporting of the study.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:35:27.724542+00:00

DOI: 10.3390/nu14224823 · PMC9698931